References
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet365(9472), 1687–1717 (2005).
- Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet369(9561), 559–570 (2007).
- Fisher B, Dignam J, Wolmark N et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet353(9169), 1993–2000 (1999).
- Dignam JJ, Fisher B. Occurrence of stroke with tamoxifen in NSABP B-24. Lancet355(9206), 848–849 (2000).
- Jordan VC, Collins MM, Rowsby L, Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol.75(2), 305–316 (1977).
- Stearns V, Johnson MD, Rae JM et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst.95(23), 1758–1764 (2003).
- Crewe HK, Ellis SW, Lennard MS, Tucker GT. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol.53(2), 171–178 (1997).
- Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol.23(36), 9312–9318 (2005).
- Rae JM, Sikora MJ, Henry NL et al. Cytochrome P450 2D6 activity predicts adherence to tamoxifen therapy. Proceedings of the San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 12–16 December 2007 (Abstract 77).
- Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst.97(1), 30–39 (2005).
- Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat.101(1), 113–121 (2007).
- Punglia RS, Winer EP, Weeks JC, Burstein HJ. Could treatment with tamoxifen be superior to aromatase inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis. J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings Part I.25(Suppl. 18), 502 (2007).
- Bonanni B MP, Johansson H, Macis D et al. Risk stratification based on the CYP2D6 tamoxifen metabolizing gene within the Italian tamoxifen prevention trial. Proceedings of the San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 12–16 December 2007 (Abstract 29).
- Connolly MRM, Barron TI, Feely J, Kennedy MJ. Co-prescription rates of tamoxifen and CYP2D6 inhibitors: are we compromising breast cancer outcome? Proceedings of the San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 12–16 December 2007 (Abstract 2099).